PT  - JOURNAL ARTICLE
AU  - MW Pletz
AU  - A Steiner
AU  - M Kesselmeier
AU  - B Löffler
AU  - S Trommer
AU  - S Weis
AU  - J Maschmann
AU  - A Stallmach
TI  - Impact of universal masking in health care and community on SARS-CoV-2 spread
AID  - 10.1101/2020.09.02.20187021
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.02.20187021
4099  - http://medrxiv.org/content/early/2020/09/08/2020.09.02.20187021.short
4100  - http://medrxiv.org/content/early/2020/09/08/2020.09.02.20187021.full
AB  - Universal masking the health care setting and in the community to contain the spread of SARS-CoV-2 has been recently recommended by the WHO, but supporting data are rare. The City of Jena was the first community in Germany to issue an order on mandatory public masking. Here, we report the development of the number of novel infections in our hospital and in the city of Jena after implementation of universal masking in our hospital and the city.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMP was supported by a grant from the German Ministry of Education and Research (BMBF No. KI1501). MK was supported by the Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC) at the Jena University Hospital, funded by the German Ministry of Education and Research (BMBF No. 01EO1502).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [author initials], upon reasonable request.